Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Changes of Hydration Measures in Elite National Collegiate Athletic Association Division I Wrestlers.

Borden EC, Kraemer WJ, Walrod BJ, Post EM, Caldwell LK, Beeler MK, DuPont WH, Anders JP, Martini ER, Volek JS, Maresh CM.

Int J Sports Physiol Perform. 2019 Oct 2:1-4. doi: 10.1123/ijspp.2019-0059. [Epub ahead of print]

PMID:
30958064
2.

Interferons α and β in cancer: therapeutic opportunities from new insights.

Borden EC.

Nat Rev Drug Discov. 2019 Mar;18(3):219-234. doi: 10.1038/s41573-018-0011-2. Review.

PMID:
30679806
3.

The Effects of a Korean Ginseng, GINST15, on Perceptual Effort, Psychomotor Performance, and Physical Performance in Men and Women.

Caldwell LK, DuPont WH, Beeler MK, Post EM, Barnhart EC, Hardesty VH, Anders JP, Borden EC, Volek JS, Kraemer WJ.

J Sports Sci Med. 2018 Mar 1;17(1):92-100. eCollection 2018 Mar.

4.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

5.

Adjuvant Chemotherapy for Stage II Rectal Cancer.

Deming D, Uboha N, Zafar SY, Rosenberg S, Bassetti M, Glasgow S, Borden EC, Lubner S.

Semin Oncol. 2015 Dec;42(6):e99-107. doi: 10.1053/j.seminoncol.2015.09.033. Epub 2015 Sep 21. Review. No abstract available.

PMID:
26615141
6.

Prevalence of circulating tumor cells in localized prostate cancer.

Khurana KK, Grane R, Borden EC, Klein EA.

Curr Urol. 2013 Nov;7(2):65-9. doi: 10.1159/000356251. Epub 2013 Oct 30.

7.

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI.

Cancer Biol Ther. 2014 Aug;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19.

8.

Interferons and their stimulated genes in the tumor microenvironment.

Cheon H, Borden EC, Stark GR.

Semin Oncol. 2014 Apr;41(2):156-73. doi: 10.1053/j.seminoncol.2014.02.002. Epub 2014 Feb 14. Review.

9.

Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation.

Ma J, Tang X, Wong P, Jacobs B, Borden EC, Bedogni B.

J Biol Chem. 2014 Mar 21;289(12):8442-9. doi: 10.1074/jbc.M113.516039. Epub 2014 Feb 3.

10.

Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL.

Clin Cancer Res. 2013 Jul 15;19(14):3996-4007. doi: 10.1158/1078-0432.CCR-12-2079. Epub 2013 Apr 15.

11.

An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.

Zhang K, Wong P, Duan J, Jacobs B, Borden EC, Bedogni B.

Pigment Cell Melanoma Res. 2013 May;26(3):408-14. doi: 10.1111/pcmr.12089. Epub 2013 Apr 2. Erratum in: Pigment Cell Melanoma Res. 2013 Jul;26(4):601.

PMID:
23480537
12.

The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.

Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC.

J Transl Med. 2012 Dec 5;10:241. doi: 10.1186/1479-5876-10-241.

13.

Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC.

Matrix Biol. 2013 Mar 11;32(2):123-32. doi: 10.1016/j.matbio.2012.11.010. Epub 2012 Nov 30.

14.

Phase I trials of targeted anticancer drugs: a need to refocus.

Borden EC, Dowlati A.

Nat Rev Drug Discov. 2012 Dec;11(12):889-90. doi: 10.1038/nrd3909.

PMID:
23197020
15.

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Zhang K, Wong P, Zhang L, Jacobs B, Borden EC, Aster JC, Bedogni B.

Oncogene. 2012 Oct 25;31(43):4609-18. doi: 10.1038/onc.2011.606. Epub 2012 Jan 16.

16.

Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.

Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC.

Oncotarget. 2011 Dec;2(12):1155-64.

17.

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.

Cheriyath V, Kuhns MA, Jacobs BS, Evangelista P, Elson P, Downs-Kelly E, Tubbs R, Borden EC.

Oncogene. 2012 Apr 26;31(17):2222-36. doi: 10.1038/onc.2011.393. Epub 2011 Sep 26.

PMID:
21996729
18.

VB-111 for cancer.

Triozzi PL, Borden EC.

Expert Opin Biol Ther. 2011 Dec;11(12):1669-76. doi: 10.1517/14712598.2011.618122. Epub 2011 Oct 1. Review.

PMID:
21961496
19.

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.

Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J.

Neuro Oncol. 2011 Jun;13(6):591-9. doi: 10.1093/neuonc/nor042.

20.

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC.

Br J Cancer. 2011 Mar 15;104(6):957-67. doi: 10.1038/bjc.2011.42. Epub 2011 Mar 1.

21.

Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial.

Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P.

J Interferon Cytokine Res. 2011 May;31(5):433-40. doi: 10.1089/jir.2010.0054. Epub 2011 Jan 15.

22.

Interferon-stimulated genes and their protein products: what and how?

Borden EC, Williams BR.

J Interferon Cytokine Res. 2011 Jan;31(1):1-4. doi: 10.1089/jir.2010.0129.

PMID:
21226605
23.

Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer.

Cheriyath V, Leaman DW, Borden EC.

J Interferon Cytokine Res. 2011 Jan;31(1):173-81. doi: 10.1089/jir.2010.0105. Epub 2010 Oct 12. Review.

24.

Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands.

West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV.

Nature. 2010 Oct 21;467(7318):972-6. doi: 10.1038/nature09421. Epub 2010 Oct 3.

25.

Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.

Luszczek W, Cheriyath V, Mekhail TM, Borden EC.

Mol Cancer Ther. 2010 Aug;9(8):2309-21. doi: 10.1158/1535-7163.MCT-10-0309. Epub 2010 Aug 3.

26.

Personalizing medicine for cancer: the next decade.

Borden EC, Raghavan D.

Nat Rev Drug Discov. 2010 May;9(5):343-4. doi: 10.1038/nrd3168.

PMID:
20431554
27.

Apoptosis: a clinical perspective.

Borden EC, Kluger H, Crowley J.

Nat Rev Drug Discov. 2008 Dec;7(12):959. doi: 10.1038/nrd2756. No abstract available.

PMID:
19065702
28.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.

29.

Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.

Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2008 Dec;28(12):733-40. doi: 10.1089/jir.2008.0030.

PMID:
18937547
30.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.

PMID:
18235122
31.

Melanoma 2007: current state and preview of the future.

Borden EC.

Semin Oncol. 2007 Dec;34(6):449-51. No abstract available.

PMID:
18083367
32.

Interferons at age 50: past, current and future impact on biomedicine.

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR.

Nat Rev Drug Discov. 2007 Dec;6(12):975-90. Review.

33.

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC.

Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.

34.

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC.

J Clin Invest. 2007 Oct;117(10):3107-17.

35.

Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.

Borden EC.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):491-501. Epub 2007 Aug 6. Review.

36.
37.

Intimal pulmonary artery sarcoma presenting as dyspnea: case report.

Hsing JM, Thakkar SG, Borden EC, Budd GT.

Int Semin Surg Oncol. 2007 Jun 29;4:14.

38.

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.

Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC.

J Clin Oncol. 2007 Jun 10;25(17):2406-13.

PMID:
17557954
39.
40.

Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.

Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, Faber P, Bukowski R, Tong K, Borden EC.

Clin Pharmacol Ther. 2007 Mar;81(3):354-61.

PMID:
17339865
41.

Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.

Thakkar SG, Peereboom D, Olencki T, Jacobs B, Elson P, Rybicki L, Lindner DJ, Borden EC.

J Interferon Cytokine Res. 2006 Nov;26(11):800-3.

PMID:
17115898
42.

Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

Li J, Lindner DJ, Farver C, Borden EC, Yi T.

Cancer Chemother Pharmacol. 2007 Aug;60(3):341-9. Epub 2006 Nov 14.

PMID:
17103170
43.

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC.

J Clin Oncol. 2006 Aug 10;24(23):3771-9. Epub 2006 Jun 26.

PMID:
16801630
44.

IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.

Taylor KL, Oates RK, Grane R, Leaman DW, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2006 May;26(5):353-61.

PMID:
16689662
45.

Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer.

Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF.

Br J Cancer. 2006 May 22;94(10):1465-71.

46.

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.

Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC.

Cancer Res. 2006 Mar 1;66(5):2785-93.

47.

Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.

Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A.

Am J Clin Oncol. 2006 Feb;29(1):59-61.

PMID:
16462504
48.

Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.

Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T.

J Immunol. 2005 Nov 15;175(10):7003-8.

49.

Review: Milstein Award lecture: interferons and cancer: where from here?

Borden EC.

J Interferon Cytokine Res. 2005 Sep;25(9):511-27.

PMID:
16181052
50.

Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.

Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS, Borden EC, Li J, Virgin HW, Zhang DE.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):496-506.

PMID:
16139798

Supplemental Content

Loading ...
Support Center